Skip to content

There's never been a greater need for safe, effective antivirals

  • Viruses (viral diseases) cause immense human suffering, particularly in developing counties
  • 95% of the viral diseases affecting humans have no approved antiviral treatment
  • Warming trends and other factors are worsening these problems
  • Covid-19 was a warning shot – there will be more pandemics
  • Vaccines will not be ready and waiting when the next pandemic occurs
  • Broad-spectrum antivirals are needed for the treatment of diseases and for pandemic preparedness.

The VTose Platform for broad-spectrum antiviral development

Driven by a desire to reduce suffering in the world, Kimer Med has taken on this challenge. Since our founding in 2020, we’ve built and tested an internal platform for the rapid development of modular, broad-spectrum antivirals. Using our platform, we’ve created antiviral compounds that, to date, have shown broad-spectrum efficacy against a range of different viruses, including Dengue and Zika.

We are in the process of conducting further testing against more human viruses, and planning for in vivo (animal) studies before we begin Phase 1 clinical trials. In August 2023 we launched our Series A capital round to raise the necessary funds to conduct clinical trials, and eventually to bring these life-saving antiviral drugs to market.

Invest for Impact

The immense harm caused by viral disease

The harm caused to human life by pathogenic viruses is on an enormous scale. Historically, viruses such as smallpox killed hundreds of millions – perhaps over 300 million as late as the 20th century. The polio virus paralysed over 15,000 people every year. The 1918 flu pandemic may have killed upwards of 100 million!

More recently, the Covid-19 pandemic broke the world, with over 700 million confirmed cases contributing to nearly 7 million deaths and causing economic harm of over ND$20 trillion dollars.

Around 370 million people are infected with Hepatitis B, 40 million with HIV, countless millions more with Herpes Simplex 1 and 2 viruses, and hundreds of millions with Human Papilloma virus (HPV). About 450 million people are infected by Dengue each year, and around a billion with various strains of the influenza virus.

Climate and environmental factors are accelerating the spread of viral diseases

To make matter worse, warming trends, habitat loss and urban expansion are causing increased severity and expansion of infectious diseases, as well as driving the emergence of new viral threats. It’s predicted that by 2050, 500 million more people will be at risk from mosquito-borne diseases.

Vaccines alone are not the solution

While vaccination has been an effective approach to reduce the spread of many viruses, other viruses have proven difficult to vaccinate against. Vaccines also take time to develop, and viruses with a high mutation rate will eventually evade any fixed vaccine, requiring constant revision and re-vaccination.

The fact is, vaccines will not be ready and waiting when the next viral pandemic strikes, so antivirals must be developed in readiness to meet these threats.

Broad spectrum antivirals can be stockpiled for pandemic preparedness

Broad spectrum antivirals are urgently required. The ideal antiviral drugs would effectively treat a range of viruses, both known and yet-to-emerge. They would also provide protection against the threat of bioterror and biowarfare events, and accidental release of viral agents.

Based on our research, the available evidence, and our results to date, we believe that genuinely broad-spectrum antivirals are well within our grasp.

If you can help us (donate, invest, partnership), please don’t hesitate to get in touch.

Contact us

Significant milestones

Aug 2020 – Kimer Med founded by Rick Kiessig and Phil Oliver
Nov 2020 – First fabrication run of our antiviral protein compound completed
Mar 2021 – Seed funding round closed with $4.2M raised
Apr 2021 – Registered our product trademark in New Zealand - VTose®
Apr 2021 – Awarded 'Getting Started' grant from Callaghan Innovation
May 2021 – First successful test against Dengue virus
Jul 2021 – Set up our Nelson HQ office
Aug 2021 – Exclusive licence with MIT for the only remaining DRACO-related patent
Oct 2021 – Fabricated a range of formulation variants, some of which yielded positive test results
Jan 2022 – Confirmed the dsRNA binding aspect of our compound's mechanism of action
Feb 2022 – Completed month long study establishing conditions under which our compound is stable
Mar 2022 – Discovered significant protein fabrication process improvements
May 2022 - Employed Andy Clover, Communications and Funding Specialist
Jun 2022 – Awarded R&D Project Grant from Callaghan Innovation
July 2022 - Employed Dr Mike Schmidt, Business Development Manager
Nov 2022 - Set up our own PC2 Laboratory in Nelson
Dec 2022 - Employed Emma Carson, Laboratory & Office Manager
Feb 2023 - Won Nelson Chamber of Commerce Business Innovation Award
May 2023 - Employed Dr Rishi Pandey, Lead Scientist
Jun 2023 - Announced 100% positive test results against Dengue (serotypes 1 and 2) and Zika viruses
Jul 2023 – Awarded Arohia Seed Grant from Callaghan Innovation
Aug 2023 – Freedom to Operate (FTO) search complete, multiple patent investigations begun
Sep 2023 – Employed Tanja Wiles, Biomedical Laboratory Technician
Sep 2023 - Launched Series A capital raise
Jan 2024 - Employed Dr Sasini Polwatta, Biomedical Scientist
Feb 2024 - Positive test results against Dengue (all four serotypes), and HSV-2 announced (100%)
Mar 2024 - Small scale in vivo study confirms safety and antiviral efficacy in living organisms
Back To Top